These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8493214)

  • 1. [Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
    Dorval T; Beuzeboc P; Garcia-Giralt E; Jouve M; Livartowski A; Palangie T; Pouillart P
    Presse Med; 1993 Jan; 22(3):104-8. PubMed ID: 8493214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
    Long HJ; Nelimark RA; Su JQ; Garneau SC; Levitt R; Goldberg RM; Poon MA; Kugler JW
    Gynecol Oncol; 1994 Aug; 54(2):180-3. PubMed ID: 8063243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
    Vallejos C; Solidoro A; Gómez H; Castellano C; Barriga O; Galdos R; Casanova L; Otero J; Rodriguez W
    Gynecol Oncol; 1997 Nov; 67(2):168-71. PubMed ID: 9367702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
    Li XP; Cui H; Zhou JW; Wei LH; Wang JL; Zhao Y; Wang Y; Wang SJ; Zhu HL; Dong L; Zhang H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):724-7. PubMed ID: 19087535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
    J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
    Cadron I; Jakobsen A; Vergote I
    Gynecol Obstet Invest; 2005; 59(3):126-9. PubMed ID: 15604591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
    Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The potentials of combined chemotherapy in disseminated ovarian cancer].
    Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
    Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.